Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000180012 | SCV000232346 | pathogenic | not provided | 2015-01-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001390616 | SCV001592405 | pathogenic | Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 10 | 2021-04-01 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the DOK7 protein. Other variants that disrupt this region (p.Cys412*, p.Gln460*, p.Gly479Hisfs*13) have been observed in individuals with DOK7-related conditions (PMID: 20458068, 20012313, 28716243). This suggests that this may be a clinically significant region of the protein. This variant has been observed in individual(s) with congenital myasthenic syndrome (PMID: 22884442, 28024842). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 198626). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the ExAC database. This sequence change creates a premature translational stop signal (p.Lys320Serfs*136) in the DOK7 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 185 amino acid(s) of the DOK7 protein. |
OMIM | RCV003221839 | SCV003842199 | pathogenic | Congenital myasthenic syndrome 10 | 1992-01-01 | no assertion criteria provided | literature only |